Trial Profile
A randomized placebo-controlled study in patients with a Gallium-68 DOTATATE PET/CT positive, clinically non-functioning pituitary macroadenoma (NFMA) of the effect of Lanreotide autosolution on Tumor (adenoma) size
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Pituitary adenoma
- Focus Therapeutic Use
- Acronyms GALANT
- 06 Jun 2021 This trial has been completed in Netherland according to European Clinical Trials Database record.
- 07 Oct 2017 Status changed from not yet recruiting to recruiting.
- 17 Jul 2015 New trial record